TRH
A hypothalamic tripeptide that drives TSH release from the pituitary while acting as a broad CNS neuromodulator with arousal-promoting and neuroprotective effects.
TRH (thyrotropin-releasing hormone) is a three-amino-acid hypothalamic peptide best known as the master regulator of TSH secretion from the pituitary. Beyond the thyroid axis it is widely distributed throughout the central nervous system, where it modulates dopaminergic, cholinergic, and serotonergic signaling to promote arousal, wakefulness, and neuroprotection. It was once FDA-approved as a diagnostic agent (Thypinone, Relefact TRH) for thyroid testing; today it is investigational for cognitive and neuroprotective uses and available through compounding pharmacies.
Class
Hypothalamic tripeptide (pGlu-His-Pro-NH2)
Half-life
~5-6 minutes
Routes
Intranasal, Intravenous, Subcutaneous
Category
Hormone & Reproductive
Researched benefits
What it's studied for
Cognitive enhancement
A double-blind human trial found that high-dose intravenous TRH attenuated scopolamine-induced memory impairment, consistent with a facilitatory role in cholinergic cognition. Evidence remains limited to small mechanistic studies.
Neuroprotection
In preclinical brain-injury models TRH prevented depletion of cortical acetylcholine and monoamines following head injury, suggesting a neuroprotective neuromodulatory role by normalizing cholinergic and noradrenergic balance.
Arousal and wakefulness
Centrally administered TRH exerts analeptic, arousal-promoting effects and can rapidly reverse sedation from barbiturates, ethanol, and opioids in animal studies, pointing to a direct CNS excitatory role independent of the thyroid axis.
Antidepressant signals
TRH is studied as a potential antidepressant, tied to its modulation of dopaminergic and serotonergic neurotransmission across the cortex, hippocampus, and limbic system. Evidence is preliminary.
Thyroid axis regulation
As the primary hypophysiotropic factor for TSH, TRH stimulates TSH and prolactin release, forming the basis of the historical TRH stimulation test for thyroid function.
Mechanism
How it works
TRH is a hypothalamic tripeptide (pGlu-His-Pro-NH2) that binds the G-protein-coupled receptors TRH-R1 and TRH-R2. In its classical endocrine role, TRH released from the hypothalamus travels to the anterior pituitary and stimulates the secretion of thyroid-stimulating hormone (TSH) and prolactin, positioning it at the top of the hypothalamic-pituitary-thyroid axis.
Beyond this hypophysiotropic function, TRH acts as a widespread CNS neuromodulator. Its receptors are expressed in the cerebral cortex, hippocampus, limbic system, and spinal cord, where TRH influences arousal, mood, and locomotor activity independent of the pituitary-thyroid axis. It modulates dopaminergic, cholinergic, and serotonergic neurotransmitter systems, producing analeptic (arousal-promoting) effects that can reverse sedation from barbiturates, ethanol, and opioids.
In injury contexts, TRH appears to preserve neurotransmitter homeostasis: preclinical work shows it prevents the post-injury rise in cortical acetylcholine and the reduction in norepinephrine that accompany concussion-related disturbances of consciousness. This normalization of cholinergic and noradrenergic balance is proposed as the basis for its arousal and neuroprotective actions.
A major limitation is TRH's very short plasma half-life (roughly 5 minutes) due to rapid enzymatic degradation, which has hampered clinical translation. This has motivated interest in more metabolically stable analogues such as taltirelin (TA-0910), approved in Japan for spinocerebellar degeneration, and in alternative delivery routes such as intranasal administration to bypass peripheral degradation.
Dosing protocols
Dosing & administration
Dosing reflects protocols reported in research and community literature for educational purposes. It is not medical advice or a recommendation. Most peptides here are not approved for human use.
Diagnostic (TRH stimulation test)
- Dose
- 200-500 mcg
- Frequency
- Single dose
- Timing
- IV bolus with serial TSH/prolactin sampling
- Duration
- Single test
- Route
- Intravenous
Historical diagnostic use for thyroid function testing; largely replaced by modern ultrasensitive TSH assays.
Research (cognition, memory)
- Dose
- 0.5 mg/kg
- Frequency
- Single dose
- Timing
- As used in controlled human study
- Duration
- Study-defined
- Route
- Intravenous
High-dose IV regimen used in the double-blind scopolamine memory-impairment trial; not an established therapeutic protocol.
- TRH's very short half-life (~5 minutes) means peripheral dosing produces only brief exposure; intranasal delivery has been explored in preclinical work to bypass peripheral degradation.
- Exogenous TRH for nootropic or energy applications is available only as a research peptide with no approved indication for these uses.
- The historical diagnostic stimulation test has largely been replaced by modern ultrasensitive TSH assays.
- Dosing figures reflect research and diagnostic contexts and are not established treatment protocols.
Evidence
Research & clinical studies (2)
TRH attenuates scopolamine-induced memory impairment in humans
In a double-blind controlled trial, high-dose intravenous TRH (0.5 mg/kg) markedly attenuated scopolamine-induced impairment on a memory task in healthy controls, providing the first human evidence for a facilitatory TRH effect on cholinergic cognition.
PMID 2104988Thyrotropin releasing hormone prevents abnormalities of cortical acetylcholine and monoamines in mice following head injury
In a mouse concussion model, TRH pretreatment prevented both the post-injury rise in cortical acetylcholine and the reduction in norepinephrine, identifying normalization of cholinergic and noradrenergic balance as a mechanism for TRH's arousal and neuroprotective effects.
PMID 9272630Safety
Side effects & considerations
Commonly reported effects
Contraindications & cautions
- Hyperthyroidism
- Cardiac arrhythmias
- Hypertension
- Epilepsy
TRH carries a moderate risk profile in research contexts. Because it stimulates the thyroid axis and has CNS excitatory (analeptic) activity, caution is warranted in people with thyroid disorders, cardiovascular disease, or seizure history. Review contraindications and consult a qualified professional before use.
FAQ
TRH — common questions
What is TRH?
TRH (thyrotropin-releasing hormone) is a hypothalamic tripeptide that is the primary regulator of TSH secretion from the pituitary. It is also widely distributed throughout the CNS as an independent neuromodulator affecting dopaminergic, cholinergic, and serotonergic systems, with arousal-promoting and neuroprotective effects independent of its thyroid-axis role.
What is TRH primarily studied for?
Its main research areas are cognitive enhancement, neuroprotection, antidepressant effects, and arousal/wakefulness. It is also used historically as a diagnostic agent for thyroid function testing.
Is TRH FDA-approved?
TRH was formerly FDA-approved as Thypinone and Relefact TRH for diagnostic TSH testing, but both products were voluntarily discontinued. It is currently not approved for any cognitive or neuroprotective use; it appears on the FDA 503A Category 1 bulks list for compounding and is available by prescription.
Why does TRH have such a short duration of action?
TRH has a plasma half-life of roughly 5 minutes because it is rapidly broken down by enzymes. This short duration has limited its clinical use and motivated interest in more stable analogues like taltirelin and in intranasal delivery.
What is taltirelin?
Taltirelin (TA-0910) is a more metabolically stable synthetic analogue of TRH. It is approved in Japan for spinocerebellar degeneration and is the only approved clinical application in this research space.
What are the main safety considerations for TRH?
Reported contraindications include hyperthyroidism, cardiac arrhythmias, hypertension, and epilepsy. Because TRH stimulates the thyroid axis and has CNS excitatory activity, it carries a moderate risk profile and should be reviewed with a qualified healthcare professional.
How is TRH administered?
Research and diagnostic use has involved intravenous, subcutaneous, and intranasal routes. Intranasal delivery has been explored in preclinical work to bypass the rapid peripheral degradation that limits peripheral dosing.
